← All trials
NCT04364997
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2020
- Primary completion
- Aug 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Apr 28, 2020
- Last posted
- Apr 28, 2020
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shijiazhuang Pharma Group (CSPC)Lead sponsor
- Shijiazhuang Pharma Group (CSPC)Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.